Who am I?
Consultant strategist providing competitive and market intelligence to investors in the biopharmaceutical industry ; founder of Qstat Consulting, a boutique strategic consulting firm specialized in competitive markets in Life Sciences industry [http://www.qstatconsulting.com]. In this role, I drive market and competitive intelligence research (primary & secondary) to enable investment strategies and translate findings into critical insights.
What do we offer?
Depending on the requested depth of analysis, we provide primary and secondary research for Key Intelligence Topics (KITs) and Key Intelligence Questions (KIQs).
Under a professional code of conduct, the consultant legally and ethically identify corporate information using a questionnaire technique.
We provide insights and detailed forecast of corporate strategies, which are essential for an investment decision making-process (e.g. the exact release date of trial data, any side-effects, safety or lack of efficacy to be further investigated, go-to-market plans, pricing structure, global regulatory and medical activities)
The secondary framework combines data about the company, drug(s) of interest (summary, patents and generics, regulatory, pre-marketing, preclinical and clinical activities, pricing, market target), marketing research, upcoming milestones, internal strengths and weaknesses, external opportunities and threats, competitive profile matrix (innovation, use of corporate assets, financial soundness, long-term investment, global competitiveness, acquisition, product diversification, product quality, marketing, R&D, patents...)
Primary and secondary data can be combined together to create a full-report, which confidential data are essential in the investment strategy.
My name is Joel Badeaux, and I'm a full-time physician (MD, MPH) and part-time investor. I'm attracted to innovative companies that have the potential to disrupt the status quo, make our world a better place, and to make money for investors as well. I only invest long in companies and never short.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I have a Bachelors Degree In Business Administration. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks.
I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com and in addition I post stock market news on my other website Wallstreetrain.com
I have a Bachelors Degree in Business Administration and have started up a website with the top 25 biotech stocks. I have been investing in biotech stocks for the last five years, and have done very well. My investing centers around being in long term in biotech stocks, because of the long term value potential. I like the risks in the biotech sector, along with the huge rewards.